Warfarin and other anticoagulants monitoring of patients during the COVID-19 pandemic, MHRA
MHRA has published guidance following concerns over an apparent increase in the number of patients taking warfarin found to have elevated INR values during the pandemic; and reminds healthcare professionals and patients that continued close INR monitoring is crucial. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - October 15, 2020 Category: Consumer Health News Source Type: news
Warfarin and other anticoagulants – monitoring of patients during the COVID-19 pandemic
The Medicines and Healthcare products Regulatory Agency (MHRA) has issued guidance on Warfarin and other anticoagulants– monitoring of patients during the COVID-19 pandemic.
Further informatio (Source: Royal Pharmaceutical Society News)
Source: Royal Pharmaceutical Society News - October 13, 2020 Category: Drugs & Pharmacology Source Type: news
Drugs to Avoid in Patients on DOACs Drugs to Avoid in Patients on DOACs
DOACs overall have substantially fewer drug-drug interactions than warfarin, but there are still a few to watch out for.Medscape Internal Medicine (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - July 23, 2020 Category: Cardiology Tags: Cardiology Clinical Case Source Type: news
DOACs Linked to Lower Fracture Risk vs Warfarin in AFib Patients DOACs Linked to Lower Fracture Risk vs Warfarin in AFib Patients
A recent population-based cohort study is one of the latest reports to suggest direct oral anticoagulants could have an edge over warfarin for preventing fractures.Medscape Medical News (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - May 21, 2020 Category: Endocrinology Tags: Diabetes & Endocrinology News Source Type: news
Osteoporotic Fracture Risk Lower for DOAC Than Warfarin in A-Fib
MONDAY, May 18, 2020 -- For patients with atrial fibrillation (AF), the risk for osteoporotic fracture appears to be lower with direct oral anticoagulant (DOAC) use compared with warfarin use, according to a study published online May 19 in the... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - May 18, 2020 Category: Pharmaceuticals Source Type: news
AMP recommends minimum set of pharmacogenetic alleles to help standardize clinical genotyping testing for warfarin response
(Association for Molecular Pathology) AMP has published consensus, evidence-based recommendations to aid in the design, validation and interpretation of clinical genotyping tests for the prediction of warfarin response. The manuscript, 'Recommendations for Clinical Warfarin Sensitivity Genotyping Allele Selection: A Joint Recommendation of the Association for Molecular Pathology and College of American Pathologists,' was released online ahead of publication in The Journal of Molecular Diagnostics. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - May 5, 2020 Category: International Medicine & Public Health Source Type: news
Costs in warfarin-sensitive versus warfarin-insensitive patients
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - April 30, 2020 Category: Drugs & Pharmacology Source Type: news
Cautions Raised Against Off-Label DOACs to Clear LV Thrombi Cautions Raised Against Off-Label DOACs to Clear LV Thrombi
Oral anticoagulation rules for left ventricular thrombus, but trial guidance is in short supply. Tempting as they may be for the indication, the newer agents may not protect as well as warfarin.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - April 29, 2020 Category: Cardiology Tags: Cardiology News Source Type: news
Vitamin K Antagonists and Osteoporotic Fractures Vitamin K Antagonists and Osteoporotic Fractures
A new study compared the fracture risks associated with NOACs vs. warfarin among AF patients on anticoagulant therapy. Which presents a better safety profile as it relates to bone health?European Heart Journal (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 13, 2020 Category: Consumer Health News Tags: Cardiology Journal Article Source Type: news
Edoxaban Noninferior to Warfarin After Valve Surgery? Edoxaban Noninferior to Warfarin After Valve Surgery?
The first randomized trial comparing a DOAC with warfarin after bioprosthetic valve replacement surgery has been reported, but the question remains whether anticoagulation is needed at all.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - April 7, 2020 Category: Cardiology Tags: Neurology & Neurosurgery News Source Type: news
Landmark Phase 3 VOYAGER PAD Study of XARELTO ® (rivaroxaban) Plus Aspirin Shows Significant Benefit in Patients with Symptomatic Peripheral Artery Disease (PAD) after Lower-Extremity Revascularization
RARITAN, NJ, March 28, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the VOYAGER PAD study met its primary efficacy and principal safety endpoints, demonstrating the XARELTO® (rivaroxaban) vascular dose (2.5 mg twice daily) plus aspirin (100 mg once daily) was superior to aspirin alone in reducing the risk of major adverse limb and cardiovascular (CV) events by 15 percent in patients with symptomatic peripheral artery disease (PAD) after lower-extremity revascularization, with similar rates of TIMI[1] major bleeding. VOYAGER PAD is the only study to show a significant benefit using...
Source: Johnson and Johnson - March 28, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news
